– Series A financing will catalyze growth and advance novel small molecule therapeutics pipeline across various disease indications
– The funding will also be used to build an automated robotic wet lab to complete DeepCure’s vision of end-to-end AI drug discovery
BOSTON–(BUSINESS WIRE)–November 8, 2021–
DeepCure, a leader in developing novel, small molecule therapeutics using the world’s largest AI drug discovery engine, announced today the closing of a $40 million Series A financing round led by Morningside Ventures, with participation from existing investors TLV Partners, Sapir Venture Partners, and Benon Group Ltd. The Company has raised a total of $47 million in financing since its inception.
DeepCure is charting a new frontier in drug development using its AI-driven drug discovery platform and automated, robotic laboratory. The Company is developing several novel preclinical candidates across different “undruggable” classes, ranging from polypharmacology programs to protein-protein interactions and previously “impossible” specificity challenges critical in various indications in areas of high unmet medical need. With shorter timelines to develop the highest-quality drug candidate, DeepCure’s technology ensures the discovery and development of novel, small molecule drugs that were previously undiscoverable using conventional methods.
“We are delighted to welcome a top-tier syndicate of leading healthcare investors led by Morningside Ventures that support our vision of developing an end-to-end drug discovery pipeline designed, optimized, synthesized, and analyzed by AI,” said Kfir Schreiber, CEO, and Co-Founder, DeepCure. “We have made tremendous progress since founding DeepCure a few years ago, and this financing reflects strong support for our technology platform, people, strategy, and most importantly, our mission to accelerate the discovery of novel targets and therapies which were previously undruggable.”
The proceeds from the Series A financing will be used to expand DeepCure’s pipeline with five additional oncology programs and develop an automated robotic wet lab to fulfill its vision of developing drugs that are fully designed, synthesized, and tested by AI. The funding will also be used to double the headcount of its current drug discovery scientists and technologists next year, including a global expansion with the launch of two new sites in Greece and Israel.
“This investment positions us to advance our first novel small molecule compound to file for IND, advance our pipeline and realize our vision of making a significant impact for patients,” added Joseph Jacobson, Ph.D., Chief Scientific Officer, and Co-Founder, DeepCure. “We scan our entire proprietary molecular database for optimal drug candidates for each discovery program, with all of our state-of-the-art in-house AI property models simultaneously. Thus, our approach increases the effective search space beyond what was currently possible, either computationally or experimentally.” remarked Thrasyvoulos Karydis, Chief Technology Officer & Co-Founder, DeepCure.
“DeepCure’s advanced drug discovery platform is further evidence of the power of data in the realm of life sciences,” said Stephen Bruso of Morningside Ventures. “By pairing the world’s largest molecular database with sophisticated AI algorithms, DeepCure has the ability to deliver novel small molecule therapeutics to patients with significant unmet need. We are proud to partner with them in this endeavor.”
About DeepCure
Deepcure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists, and biologists. Using an end-to-end drug discovery platform and automated robotic wet lab, the Company is developing a novel pipeline of precision small molecules across many different therapeutic indications. DeepCure’s founding team includes some of the industry’s preeminent researchers and technologists. Our vision is to use AI-driven discovery to create better small molecules therapeutics and faster cures for every disease-relevant protein target. DeepCure is based in Boston, MA. For more information, visit http://www.deepcure.ai/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005309/en/
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]
VentureBeat
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more
Source: Read Full Article